Acumen Pharmaceuticals to Showcase Brain Delivery Tech and Early Alzheimer’s Data at AAIC 2026 — Acumen Pharmaceuticals, Inc.

Event summary

Acumen Pharmaceuticals will present three studies at AAIC 2026, including an oral presentation on bispecific antibodies for enhanced brain delivery.
The presentations highlight progress in EBD technology and early Alzheimer’s disease insights from the ALTITUDE-AD trial.
Collaboration with JCR Pharmaceuticals leverages transferrin-receptor-targeting tech to improve drug delivery to the brain.
Sabirnetug (ACU193), Acumen’s lead candidate, is in a Phase 2 trial with topline results expected late 2026.

The big picture

Acumen Pharmaceuticals is advancing its AβO-targeting science through strategic collaborations and patient-centered research. The focus on enhancing brain delivery of therapeutics aligns with broader industry efforts to improve the efficacy and safety of Alzheimer’s treatments. With topline results from the ALTITUDE-AD trial expected later this year, the company’s progress could have significant implications for the future of early Alzheimer’s disease management.

What we're watching

Technology Validation: Whether Acumen’s EBD technology can demonstrate superior brain delivery in preclinical models.
Clinical Trial Outcomes: The pace at which ALTITUDE-AD trial results could influence future treatment approaches for early Alzheimer’s disease.
Strategic Partnerships: How the collaboration with JCR Pharmaceuticals will impact Acumen’s pipeline and competitive positioning.